(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
EnteroBiotix declares positive outcomes from TrIuMPH phase 2a trial of EBX-102-02 in adults with irritable bowel syndrome with constipation
EnteroBiotix Limited has announced promising initial results from its TrIuMPH Phase 2a clinical trial, evaluating EBX-102-02, a next-generation microbiome therapy, for irritable bowel syndrome with constipation (IBS-C). The randomized, placebo-controlled study involved 122 adults with moderate to severe IBS-C and IBS with diarrhea (IBS-D).
Results from the IBS-C cohort (n=62) indicate that EBX-102-02 led to significant symptom improvement, including reductions in IBS Symptom Severity Score (IBS-SSS), improved stool consistency, increased bowel movements, and reduced abdominal pain. Positive effects were observed as early as week one and sustained through follow-up. The treatment was well-tolerated, with mostly mild gastrointestinal side effects and no serious adverse events.
Microbiome analysis showed that EBX-102-02 altered intestinal microbiota composition toward a healthier profile. EnteroBiotix plans a Phase 2b trial and will release full trial data, including IBS-D results, in Q3 2025. These findings support the potential of EBX-102-02 as a novel therapy for IBS.
19-03-2025